Heterocyclic modulators of lipid synthesis
US-2024400552-A1 · Dec 5, 2024 · US
Method of administration and treatment
US9192604B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9192604-B2 |
| Application number | US-201214128007-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 28, 2012 |
| Priority date | Jun 28, 2011 |
| Publication date | Nov 24, 2015 |
| Grant date | Nov 24, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
This invention relates to a method of treating cancer in a human in need thereof by determining the presence or absence of a detectable amount of a gene product of the Neurofibromin-2 (NF2) gene in a sample from the human, and administering to the human an effective amount of a focal adhesion kinase (FAK) inhibitor, or a pharmaceutically acceptable salt thereof, if no gene product or no isoform 1 gene product is detected. This invention also relates to a method of treating cancer in a human in need thereof, comprising determining the presence or absence of a detectable amount of a functional isoform 1 protein of the NF2 gene, or a functional fragment thereof, in a sample from the human, and administering to the human an effective amount of a focal adhesion kinase (FAK) inhibitor, or a pharmaceutically acceptable salt thereof, if no gene product or no isoform 1 gene product is detected.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treating cancer in a human in need thereof, comprising determining the presence or absence of a detectable amount of a gene product of the Neurofibromin-2 (NF2) gene in a sample from said human, and administering to said human an effective amount of a focal adhesion kinase (FAK) inhibitor, or a pharmaceutically acceptable salt thereof, if no gene product or no isoform 1 gene product is detected. 2. The method of claim 1 , fur…
Assignees
Inventors
Classifications
- A61K31/4439Primary
Human Necessities · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
Physics · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9192604B2 cover?
- This invention relates to a method of treating cancer in a human in need thereof by determining the presence or absence of a detectable amount of a gene product of the Neurofibromin-2 (NF2) gene in a sample from the human, and administering to the human an effective amount of a focal adhesion kinase (FAK) inhibitor, or a pharmaceutically acceptable salt thereof, if no gene product or no isoform…
- Who is the assignee on this patent?
- Auger Kurt R, Dar Mohammed M, Fleming Ronald A, and 1 more
- What technology area does this patent fall under?
- Primary CPC classification A61K31/4439. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Nov 24 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).